Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target Reuters
Covered in this story
Call it yourself
No calls on $NOVN.SW yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Novartis →Summary aggregated from Reuters's public RSS feed. The full reporting belongs to Reuters — please read it on their site.